Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from ValiRx plc ( (GB:VAL) ) is now available.
ValiRx has announced that Ambrose Healthcare has exercised its option to license the VAL401 asset from ValiSeek Limited for £16 million plus royalties. This agreement marks a significant step for ValiRx, as it allows for the further development and commercialization of VAL401, a repurposed Risperidone asset with anticancer effects. The partnership with Ambrose, a specialist pharmaceutical company, aims to advance treatments for rare diseases, including pancreatic cancer, and underscores the strategic focus on innovative therapies. The collaboration is expected to enhance ValiRx’s industry positioning and provide potential therapeutic benefits across multiple cancer indications.
More about ValiRx plc
ValiRx is a life science company focused on early-stage cancer therapeutics and women’s health, aiming to accelerate the translation of innovative science into impactful medicines. The company provides a framework for rapid translation of scientific discoveries into clinical development and connects diverse disciplines to streamline and reduce the cost of drug development. ValiRx’s lead candidates are outlicensed or partnered for further development and commercialization.
Average Trading Volume: 1,892,804
Technical Sentiment Signal: Sell
Current Market Cap: £1.78M
See more insights into VAL stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue